MDB Capital Holdings, LLC (NASDAQ:MDBH – Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 7,585 shares, a growth of 535.3% from the December 15th total of 1,194 shares. Based on an average trading volume of 18,279 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 18,279 shares, the short-interest ratio is presently 0.4 days.
MDB Capital Trading Up 0.9%
NASDAQ MDBH traded up $0.03 during trading hours on Monday, reaching $3.55. 1,736 shares of the company’s stock were exchanged, compared to its average volume of 12,103. The stock has a market cap of $36.00 million, a PE ratio of 3.82 and a beta of 1.09. MDB Capital has a one year low of $3.11 and a one year high of $7.98. The firm has a fifty day moving average of $3.43 and a 200-day moving average of $3.74.
MDB Capital (NASDAQ:MDBH – Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.46) earnings per share (EPS) for the quarter. The business had revenue of $1.42 million during the quarter.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (d)” rating on shares of MDB Capital in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
View Our Latest Analysis on MDB Capital
About MDB Capital
MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.
Featured Stories
- Five stocks we like better than MDB Capital
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Gold Breakout ALERT
- Trump’s Hand-Written Letter Will Shock his Haters
- The $100 Trillion AI Story No One Is Telling You
Receive News & Ratings for MDB Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDB Capital and related companies with MarketBeat.com's FREE daily email newsletter.
